Group 1 - Institutional reports today issued 21 buy ratings involving 20 stocks, with Huafeng Aluminum receiving the highest attention with 2 buy ratings [1] - Among the stocks rated, 10 provided future target prices, with 7 stocks showing an upside potential exceeding 20%. China Pacific Insurance has the highest upside potential at 36.86% with a target price of 47.97 yuan [1] - The average increase for stocks with buy ratings today was 0.59%, outperforming the Shanghai Composite Index, with notable gainers including Spring Autumn Electronics and Aladdin [1] Group 2 - The power equipment industry is the most favored, with stocks like Putailai and Zhenyu Technology making the buy rating list. The pharmaceutical and electronics sectors also received attention with 4 and 3 stocks respectively [2] - A detailed list of stocks with institutional buy ratings includes China Pacific Insurance, Huafeng Aluminum, and others, with various target prices and latest closing prices provided [2]

Group 1 - The core point of the article is that Harbin Sanlian Pharmaceutical Co., Ltd. has initiated a bioequivalence trial for its Fluorobufen gel patch (40mg) in healthy subjects in China, with the trial registered under CTR20254749 and first published on November 27, 2025 [1][2] - The trial aims to compare the absorption speed and extent of the test formulation against a reference formulation under fasting conditions, assessing the bioequivalence of the two formulations [1][2] - The primary endpoints of the trial include Cmax, AUC0-t, and AUC0-∞ measured over 72 hours post-administration, while secondary endpoints include Tmax, t1/2z, λz, Ct, and AUC_%Extrap, along with monitoring adverse events and other health metrics [2] Group 2 - The current status of the trial is ongoing, and recruitment has not yet started [3]

Core Viewpoint - The announcement by the National Health Commission regarding the approval of new food materials, including the protein from the fungus Veneta, signifies a regulatory milestone for the company, allowing its subsidiary to produce and sell this new food ingredient domestically [1] Company Summary - Fujian Pharmaceutical (300497.SZ) announced that its subsidiary, Jiangxi Fujian Biotechnology Co., has successfully obtained administrative approval for the new food material application of Veneta fungus protein from the National Health Commission [1] - The approval indicates that the safety assessment materials submitted for Veneta fungus protein have been reviewed and passed by expert organizations [1] Industry Summary - The approval of Veneta fungus protein as a new food material aligns with the regulatory framework established by the Food Safety Law, highlighting the increasing acceptance of innovative food ingredients in the market [1] - This development may open new avenues for the production and commercialization of alternative protein sources within the food industry [1]

Core Viewpoint - The approval of the acetate prednisolone by the National Medical Products Administration marks a significant development for the company, as it expands its product offerings in the treatment of various inflammatory diseases [1] Company Summary - The company, Xinhua Pharmaceutical, has received the approval for the acetate prednisolone chemical raw material drug listing application, which is primarily used for allergic and autoimmune inflammatory diseases [1] - The drug is currently utilized for conditions such as active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, nephrotic syndrome, thrombocytopenic purpura, neutropenia, various adrenal cortex insufficiencies, severe dermatitis, and acute leukemia, as well as in the comprehensive treatment of certain infections [1] Industry Summary - According to relevant statistics, the sales revenue of acetate prednisolone-related formulations in Chinese public medical institutions is projected to be approximately 100 million RMB in 2024 [1]

Core Viewpoint - The National Health Commission of China has approved the safety assessment of the new food ingredient, Venetian Sclerotium Protein, as part of its announcement regarding 14 new food items [1] Group 1 - The announcement is documented as No. 7 of 2025 by the National Health Commission [1] - The approval follows a review of safety assessment materials submitted for the new food ingredient [1] - The review was conducted by expert evaluators organized by the National Health Commission [1]

山东新华制药股份(00719.HK)发布公告，近日，公司收到国家药品监督管理局核准签发的醋酸泼尼松龙 《化学原料药上市申请批准通知书》。 ...

Core Viewpoint - The company, Xinhua Pharmaceutical, has received approval from the National Medical Products Administration for the marketing application of Acetate Prednisone, which is primarily used for allergic and autoimmune inflammatory diseases [1] Group 1: Product Approval - The approval notification allows the company to market Acetate Prednisone as a chemical raw material [1] - This product is indicated for various conditions including active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, nephrotic syndrome, thrombocytopenic purpura, neutropenia, adrenal insufficiency, severe dermatitis, and acute leukemia [1] - Acetate Prednisone is also utilized in the comprehensive treatment of certain infections [1]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the marketing application of Acetate Prednisolone, which is primarily used for allergic and autoimmune inflammatory diseases [1] Group 1: Product Approval - The approval includes a notification for the marketing of Acetate Prednisolone as a chemical raw material drug [1] - The drug is indicated for various conditions including active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, nephrotic syndrome, thrombocytopenic purpura, granulocytopenia, adrenal cortical insufficiency, severe dermatitis, and acute leukemia [1] - It is also used in the comprehensive treatment of certain infections [1]

Core Viewpoint - The approval of the acetate prednisolone raw material drug by the National Medical Products Administration is expected to enhance the company's product line and competitiveness in the hormone drug market [1] Group 1: Company Developments - The company received the approval notice for the acetate prednisolone chemical raw material drug application from the National Medical Products Administration [1] - The application for this raw material drug was submitted in March 2024 and has been accepted for review [1] - The approval is anticipated to enrich the company's hormone product line [1] Group 2: Market Context - The acetate prednisolone is primarily used for allergic and autoimmune inflammatory diseases [1] - The estimated sales revenue for acetate prednisolone formulations in Chinese public medical institutions is approximately 100 million yuan in 2024 [1] - The sales of the drug may be influenced by industry policies and market conditions, indicating potential uncertainties [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the listing of Acetate Prednisolone as a chemical raw material drug, indicating a significant advancement in its product portfolio and potential market opportunities [1] Company Summary - The company submitted the registration application for Acetate Prednisolone to the National Medical Products Administration's CDE in March 2024, which was accepted [1] - The approval notification for the listing was granted in November 2025, with the review conclusion being a registration approval [1] - Acetate Prednisolone is primarily used for allergic and autoimmune inflammatory diseases, including active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, nephrotic syndrome, and others [1] Industry Summary - The sales revenue of Acetate Prednisolone-related formulations in Chinese public medical institutions is estimated to be approximately RMB 100 million in 2024 [1]